RG002C0106 clinical trials
RG002C0106 is named as an intervention in 3 current clinical trials in our China and Austria registers. None are recruiting at the moment. The most common phase is Phase 1. The lead sponsor is Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. The most-studied condition is IgA Nephropathy (IgAN).
Patient leaflets for RG002C0106
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of RG002C0106
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase 1 Study to Evaluate RG002C0106 Injection in Healthy Participants
NCT07902245 · ClinicalTrials.gov ↗ · Safety Issues
|
Phase 1 | Not yet open | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd | Austria |
|
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
NCT07305974 · ClinicalTrials.gov ↗ · IgA Nephropathy (IgAN)
|
Phase 2 | Active, closed | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd | China |
|
A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment
NCT07445906 · ClinicalTrials.gov ↗ · Renal Impairments, IgA Nephropathy (IgAN)
|
Phase 1 | Active, closed | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with RG002C0106
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
| Clinical trials in Austria | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about RG002C0106 trials
How many clinical trials are testing RG002C0106?
3 current trials in our China and Austria registers name RG002C0106 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are RG002C0106 trials recruiting patients?
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors RG002C0106 clinical trials?
The lead sponsor is Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how RG002C0106 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RG002C0106 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RG002C0106 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.